500257 Stock Overview
Operates as a pharmaceutical company in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Expansion Into Complex Generics And Biosimilars Will Strengthen Future Market Position
My Notes
Capture your thoughts, links and company narrative
Lupin Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,906.15 |
| 52 Week High | ₹2,403.45 |
| 52 Week Low | ₹1,493.75 |
| Beta | 0.61 |
| 1 Month Change | -10.87% |
| 3 Month Change | -7.91% |
| 1 Year Change | 18.23% |
| 3 Year Change | 156.81% |
| 5 Year Change | 197.98% |
| Change since IPO | 63,972.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500257 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.2% | -2.2% | -0.7% |
| 1Y | 18.2% | 9.4% | -0.6% |
Return vs Industry: 500257 exceeded the Indian Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: 500257 exceeded the Indian Market which returned -0.6% over the past year.
Price Volatility
| 500257 volatility | |
|---|---|
| 500257 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: 500257 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 500257's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 19,210 | Vinita Gupta | www.lupin.com |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities.
Lupin Limited Fundamentals Summary
| 500257 fundamental statistics | |
|---|---|
| Market cap | ₹902.74b |
| Earnings (TTM) | ₹28.69b |
| Revenue (TTM) | ₹220.02b |
30.3x
P/E Ratio4.0x
P/S RatioIs 500257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500257 income statement (TTM) | |
|---|---|
| Revenue | ₹220.02b |
| Cost of Revenue | ₹71.98b |
| Gross Profit | ₹148.04b |
| Other Expenses | ₹119.35b |
| Earnings | ₹28.69b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 62.84 |
| Gross Margin | 67.28% |
| Net Profit Margin | 13.04% |
| Debt/Equity Ratio | 21.9% |
How did 500257 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 11:43 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lupin Limited is covered by 78 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |